Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PHARMACEUTICALS INC / MA

12/15/2014

12/15/2014

Stock

Stock

Common

Form 4

December 16, 2014

FORM	ПΔ								OMB APPROVAL			
	UNITED	STATES S			ND EX0 , D.C. 20		OMMISSION	OMB Number:	3235-0287			
Check the if no lon	ger		OFF 4 3 1.	GEG DI	DENTER	TOT A	EDGIND OF	Expires:	January 31, 2005			
subject t Section Form 4 c	51A1E 16.	MENT OF C	CHAN	GES IN SECUE		ICIA	ERSHIP OF	Estimated a burden hour response	verage rs per			
Form 5 obligation may con See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1940									0.5		
(Print or Type	Responses)											
1. Name and Address of Reporting Person LEIDEN JEFFREY M								5. Relationship of Reporting Person(s) to Issuer				
			A [VRT		1101	(Check all applicable)						
(Last) C/O VERT	. Date of Month/Da 2/12/20	ay/Year)	ransaction			X Director 10% Owner X Officer (give title Other (specify below)						
	CEUTICALS RATED, 50 NOF	RTHERN						CLO	o & Frestdein			
	(Street)	(Street) 4. If Amo Filed(Mo				1		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
BOSTON,	MA 02210						:	Form filed by Mo Person	ore than One Re	porting		
(City)	(State)	(Zip)	Table	e I - Non-I	Derivative	Secur	ities Acqu	ired, Disposed of,	or Beneficial	ly Owned		
1.Title of Security (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)				3. Transaction Code (Instr. 8)	4. Securit for Dispos (Instr. 3, 4	ed of (1 and 5	D)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)			
Common Stock	12/12/2014			G <u>(1)</u>	2,500 (2)	D	\$ 0	267,694	D			
Common	12/15/2014			S ⁽¹⁾	13,021	D	\$ 113.19	254,673	D			

 $S^{(1)}$

 $S^{(1)}$

13,021 D

15,440 D

113.19 254,673

114.21 239,233

(3) (4)

(4) (5)

\$

D

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Common Stock	12/15/2014	S <u>(1)</u>	6,406	D	\$ 115.05 (4) (6)	232,827	D	
Common Stock	12/15/2014	S <u>(1)</u>	3,400	D	\$ 116.27 (4) (7)	229,427	D	
Common Stock	12/15/2014	S <u>(1)</u>	8,650	D	\$ 117.26 (4) (8)	220,777	D	
Common Stock	12/15/2014	S <u>(1)</u>	2,700	D	\$ 118.05 (4) (9)	218,077	D	
Common Stock	12/15/2014	S <u>(1)</u>	200	D	\$ 119	217,877	D	
Common Stock	12/15/2014	S <u>(1)</u>	200	D	\$ 120.17	217,677	D	
Common Stock						440	I	401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	5. ionNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of lying	8. Price of Derivative Security (Instr. 5)	
				Code V	' (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners 2

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

X

Director 10% Owner Officer Other

LEIDEN JEFFREY M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210

CEO & President

Signatures

Kenneth L. Horton, Attorney-In-Fact

12/16/2014

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- (2) Represents a gift made to a charitable donor-advised fund.
- (3) Open market sales reported on this line occurred at a weighted average price of \$113.19 (range \$112.66 to \$113.65).
- (4) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (5) Open market sales reported on this line occurred at a weighted average price of \$114.21 (range \$113.66 to \$114.65).
- (6) Open market sales reported on this line occurred at a weighted average price of \$115.05 (range \$114.69 to \$115.68).
- (7) Open market sales reported on this line occurred at a weighted average price of \$116.27 (range \$115.73 to \$116.70).
- (8) Open market sales reported on this line occurred at a weighted average price of \$117.26 (range \$116.74 to \$117.73).
- (9) Open market sales reported on this line occurred at a weighted average price of \$118.05 (range \$117.74 to \$118.64).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3